Drug Trial Radar · NCT00858637
Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis
Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
260
Actual
Start
Mar 2009
Primary completion
Mar 2010
Study completion Mar 2010
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Mar 10, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate the superiority of MCI-196 over placebo and non-inferiority with simvastatin in reducing serum low-density lipoprotein (LDL)-cholesterol in subjects with chronic kidney disease Stage V on dialysis. This study incorporates a Washout Period and two treatment periods - an active comparison phase and a placebo-controlled withdrawal phase.
Conditions
- Chronic Kidney Disease
Interventions
MCI-196Drug
Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Placebo of SimvastatinDrug
Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
SimvastatinDrug
Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Placebo of MCI-196Drug
Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Serum LDL-cholesterol Levels From Week 16 to Week 20 (LOCF) (ITT2)Time frame: week20 minus week16
Locations
39 sites in 13 countries. Site status is shown where the registry gives one.
Site not named
Brest, Belarus
Site not named
Grodno, Belarus
Site not named
Homyel, Belarus
Site not named
Minsk, Belarus
Site not named
Vitebsk, Belarus
Site not named
Gabrovo, Bulgaria
Site not named
Plovdiv, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Karlovac, Croatia
Site not named
Osijek, Croatia
Site not named
Esbjerg, Denmark
Site not named
Roskilde, Denmark
Site not named
Jakarta, Indonesia
Site not named
Malang, Indonesia
Site not named
Medan, Indonesia
Site not named
Palembang, Indonesia
Site not named
Tamanlarea Makassar, Indonesia
Site not named
Ashkelon, Israel
Site not named
Nahariya, Israel
Site not named
Bellano, Italy
Site not named
Catania, Italy
Site not named
Lecco, Italy
Site not named
Merate, Italy
Site not named
Milan, Italy
Site not named
Oggiono, Italy
Site not named
Riga, Latvia
Site not named
Valmiera, Latvia
Site not named
Kaunas, Lithuania
Site not named
Kedauniai, Lithuania
Site not named
Vilnius, Lithuania
Site not named
George Town, Malaysia
Site not named
Johor Bahru, Malaysia
Site not named
Kelantan, Malaysia
Site not named
Perak, Malaysia
Site not named
Bucharest, Romania
Site not named
Timișoara, Romania
Site not named
Singapore, Singapore
Site not named
Bangkok, Thailand
Site not named
Phitsanulok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.